The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III study of pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): KEYNOTE-991.
 
Christian Gratzke
Honoraria - Bayer; Ipsen; Janssen; Olympus; Takeda
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; MSD; Olympus
Speakers' Bureau - Astellas Pharma; Bayer; Ipsen; Janssen; MSD; Takeda
 
Joseph E Burgents
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Cuizhen Niu
Employment - Merck Sharp & Dohme
Honoraria - Merck Sharp & Dohme
 
Christian Heinrich Poehlein
Employment - Merck
Leadership - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Charles G. Drake
Stock and Other Ownership Interests - Compugen; Harpoon therapeutics; Kleo Pharmaceuticals; Tizona Therapeutics, Inc.; Urogen pharma; Werewolf Therapeutics
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Compugen; F-Star; Ferring; Genocea Biosciences; Janssen Oncology; Kleo Pharmaceuticals; Merck; Merck Serono; Pfizer; Pierre Fabre; Roche/Genentech; Shattuck Labs; Tizona Therapeutics, Inc.; Urogen pharma; Werewolf Therapeutics
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Patents licensed to BMS (Inst); Patents licensed to Potenza Therapeutics (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Merck Sharp & Dohme; Pfizer; Roche/Genentech